Wire · opportunities
U.S. FDA approves Inluriyo (imlunestrant) in combination with Verzenio (abemaciclib) for ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 18 September 2026 · Fusion42 review
The U.S. FDA granted full approval to Eli Lilly's Inluriyo (imlunestrant) combined with Verzenio (abemaciclib) for treating adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer, based on data showing doubled median progression-free survival in the Phase 3 EMBER-3 trial.
This Wire brief sits within Fusion42's coverage of Biotech, and 10 sources have reported it between 18 Sep 2026 and 21 Sep 2026.
◆ ◆ The Wire takeaway
You can now offer a clinically proven oral therapy that combines hormonal and CDK4/6 inhibition without extra monitoring hurdles. The value lies in targeting resistance mutations at progression, opening direct competition with existing second-line breast cancer treatments.
◆ Coverage
10 sources · first reported 18 Sep 2026 · latest 21 Sep 2026
◆ Related on Wire
◆ Topics